Although the sample size for the liver and colon cancer cohorts was small, we achieved optimal sensitivity/specificity ratios of 50.0%/90.0% and 75.0%/100.0%, respectively, suggesting ZNF154 methylation may also be useful as a cancer marker in liquid biopsies from patients with these cancer types as well, although more extensive sample cohorts will be needed. This evidence concerns the gene ZNF154 and colonic neoplasm.